Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.46 |
| ▸ | PPARG | P37231 | 10/20 | 0.46 |
| ▸ | PPARD | Q03181 | 5/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5294723 | 0.92 | PPARA (0.55) | PPARAPPARGPPARD | |
| SCHEMBL3273896 | 0.92 | PPARA (0.55) | PPARAPPARGPPARD | |
| SCHEMBL5916231 | 0.91 | PPARA (0.54) | PPARAPPARGPPARD | |
| SCHEMBL3960794 | 0.91 | TRPM8 (0.52) | PPARAPPARGPPARDTRPM8 | |
| Water SCHEMBL5916134 | 0.91 | PPARA (0.54) | PPARAPPARGPPARD | |
| SCHEMBL5691776 | 0.90 | PPARA (0.48) | PPARAPPARGPPARDPTPN1CA12 | |
| SCHEMBL5916232 | 0.90 | PPARA (0.48) | PPARAPPARGPPARDPTPN1CA12 | |
| SCHEMBL3959647 | 0.84 | PPARA (0.55) | PPARAPPARGPPARDTRPM8ALOX5 | |
| SCHEMBL5283269 | 0.84 | FFAR1 (0.56) | PPARAPPARGTRPM8ALOX5CA12 | |
| SCHEMBL3963119 | 0.83 | PPARA (0.59) | PPARAPPARGPPARDTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514471-B2 | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor α (PPAR) | ASTRAZENECA AB (SE) | 2009-04-07 | — | — | US | disclosed |
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| US-20050171204-A1 | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | PPARA 346/4885PPARG 228/4885PPARD 623/4885 |
| US-20050171204-A1 | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | PPARA, PPARD, PPARG | PPARA 1/4885PPARG 3/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.